Russell Ulrich, DO
Geriatric Medicine · Piedmont, ALNPI 1407850126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $541 and has fallen 59.4% since, to $219 in 2025.
Across 131 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$505
- Novo Nordisk$382
- Astellas Pharma US Inc$179
- AstraZeneca$157
- Novartis$133
- GSK$131
- plus $810 from 24 others
What the payments were for
- Food & beverage$2,09891%
- Education$1999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $505 |
| Novo Nordisk | 23 | $382 |
| Astellas Pharma US Inc | 2 | $179 |
| AstraZeneca | 8 | $157 |
| Novartis | 8 | $133 |
| GSK | 9 | $131 |
| Lilly USA, LLC | 8 | $120 |
| Avanir Pharmaceuticals, Inc. | 2 | $93 |
| Dexcom, Inc. | 3 | $63 |
| Johnson & Johnson | 1 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Pfizer | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Exact Sciences | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Genentech USA, Inc. | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Amgen | 1 | $22 |
| Bayer | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$2,297 in reported general payments places this provider in the 85th percentile of 39 geriatric medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 361 | $228,845 |
| MounjaroTirzepatide | 146 | $154,193 |
| JanuviaSitagliptin Phosphate | 152 | $107,425 |
| FarxigaDapagliflozin Propanediol | 108 | $103,948 |
| JardianceEmpagliflozin | 120 | $97,908 |
| OzempicSemaglutide | 76 | $72,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $71,628 |
| Tresiba Flextouch U-200Insulin Degludec | 70 | $67,813 |
| TrulicityDulaglutide | 71 | $67,748 |
| RybelsusSemaglutide | 46 | $53,864 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $48,969 |
| JanumetSitagliptin Phos/Metformin Hcl | 46 | $43,818 |
| LinzessLinaclotide | 68 | $40,918 |
| XareltoRivaroxaban | 40 | $38,745 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $29,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $228,845361 claims |
| Lilly USA, LLCMounjaro, Trulicity | $120 | $221,940217 claims |
| MerckJanuvia, Janumet | $11 | $151,243198 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $157 | $128,836167 claims |
| Novo NordiskOzempic, Rybelsus | $382 | $126,492122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arexvy | $131 | $111,470226 claims |
| Boehringer IngelheimJardiance | $23 | $97,908120 claims |
| Johnson & JohnsonXarelto, Invokana | $50 | $50,01354 claims |
| AbbVieLinzess | $505 | $40,91868 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $41 | $27,67851 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $19,87242 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $49 | $17,87312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 39 geriatric medicine providers in Alabama.
Other geriatric medicine in Piedmont
- Donald VollmerHuntsville$229K
- Arden AylorTalladega$5K
- Joel BolenMontgomery$4K
- Ali AhmedBirmingham$3K
- Juanita HeersinkDothan$2K
- David RaderMountain Brk$2K
- Igor BidikovHeflin$1K
- Julie KnopEva$741
- Jaehneth Ewell-TaylorTuskegee$379
- Lisa CobbMoulton$264
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.